There are 449 resources available
94P - Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression
Presenter: Filip Markovic
Session: Poster Display session
95P - Understanding the real-world (RW) impact of time between treatment regimens on clinical outcomes in patients with metastatic NSCLC previously treated with immunotherapy (IO) in the US community oncology setting
Presenter: Alexander Spira
Session: Poster Display session
96P - Induction chemotherapy backbone in frail patients (pts) with advanced NSCLC treated with chemotherapy plus pembrolizumab (P): A single institution retrospective audit of dose intensities from modified regimens
Presenter: Alessia Vendittelli
Session: Poster Display session
97P - Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy
Presenter: Rupesh Kotecha
Session: Poster Display session
98TiP - Safety and efficacy of aumolertinib combined with anlotinib as 1st-line treatment in advanced lung cancer EGFR mutation with TP53 co-mutation
Presenter: Zhan Sheng Jiang
Session: Poster Display session
99TiP - A randomized phase II study of lazertinib alone versus lazertinib plus bevacizumab for advanced non-small cell lung cancer with epidermal growth factor receptor activating mutations and smoking history
Presenter: AHN Beung chul
Session: Poster Display session
100TiP - Phase II study of aumolertinib combined with local radiation therapy for EGFR mutated stage IV NSCLC patients with oligometastasis
Presenter: Fen Zhao
Session: Poster Display session
Phase II study of aumolertinib combined with local radiation therapy for EGFR mutated stage IV NSCLC patients with oligometastasis
Presenter: Fen Zhao
Session: Poster Display session
101TiP - The efficacy and safety of furmonertinib in advanced NSCLC patients with EGFR mutations and CNS metastases based on ctDNA detection in peripheral blood and CSF (FAITH)
Presenter: xiaoyan li
Session: Poster Display session
106TiP - PULSE, a non-inferiority study of maintenance pembrolizumab at usual or low dose in non-squamous lung cancer
Presenter: JORDI REMON MASIP
Session: Poster Display session